Literature DB >> 17176983

Distal bile duct carcinoma: prognostic factors after curative surgery. A series of 112 cases.

Qingbao Cheng1, Xiangji Luo, Baihe Zhang, Xiaoqing Jiang, Bin Yi, Mengchao Wu.   

Abstract

BACKGROUND: The identification of independent prognostic indicators in distal bile duct carcinomas (DBDCs) has been limited by the small number of tumors and a lack of molecular prognostic markers. Markers assessed in combination may perform better than those considered individually. We conducted this study to identify prognostic predictors of patients with DBDC with special focus on combination of expression of p53 protein and clinicopathological predictors.
METHODS: Between December 1996 and 2002, 112 consecutive patients undergoing pancreaticoduodenectomy in the Eastern Hepatobiliary Surgery Hospital for distal bile duct carcinomas were identified in a prospectively collected database. The survival of patients was comparable with respect to patient characteristics, clinicopathological factors and degree of p53 protein expression followed by a univariate and multivariate analysis.
RESULTS: Actual 1, 3, and 5-year survival rates were 85.7, 50.9, and 25.0%, respectively. By Cox proportional hazards survival analysis, the most powerful predictors of survival rate were p53 expression [relative risk (RR) 5.2, 95% CI 4.8-5.6], pancreatic invasion (RR 5.6, 95% CI 4.3-6.9), lymph nodes metastasis (RR 3.9, 95% CI 3.3-4.5), and operative time (RR 1.8, 95% CI 1.5-2.1).
CONCLUSIONS: Overexpression of p53 in DBDC is strongly associated with significantly reduced survival, independently of clinicopathological prognostic factors. The resection margin status provides little independent prognostic information. Longer operative time may have unfavorable effect on prognosis of patients with DBDC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17176983     DOI: 10.1245/s10434-006-9260-0

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  22 in total

1.  Array comparative genomic hybridization identifies novel potential therapeutic targets in cholangiocarcinoma.

Authors:  Siobhan C McKay; Kristian Unger; Stephanos Pericleous; Gordon Stamp; Gerry Thomas; Robert R Hutchins; Duncan R C Spalding
Journal:  HPB (Oxford)       Date:  2011-03-10       Impact factor: 3.647

2.  Survival outcome and prognostic factors after pancreatoduodenectomy for distal bile duct carcinoma: a retrospective multicenter study.

Authors:  Ekaterina Petrova; Felix Rückert; Sebastian Zach; YinFeng Shen; Jürgen Weitz; Robert Grützmann; Uwe A Wittel; Frank Makowiec; Ulrich T Hopt; Peter Bronsert; Florian Kühn; Bettina M Rau; Roman E Izrailov; Igor E Khatkov; Hryhoriy Lapshyn; Louisa Bolm; Dirk Bausch; Tobias Keck; Ulrich F Wellner; Gabriel Seifert
Journal:  Langenbecks Arch Surg       Date:  2017-06-13       Impact factor: 3.445

Review 3.  Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009.

Authors:  Murad Aljiffry; Mark J Walsh; Michele Molinari
Journal:  World J Gastroenterol       Date:  2009-09-14       Impact factor: 5.742

Review 4.  Current state of nonsurgical therapies for cholangiocarcinoma.

Authors:  Volker Brass; Jan B Kuhlmann; Hubert E Blum
Journal:  Hepat Oncol       Date:  2013-12-20

Review 5.  The survival outcome and prognostic factors for distal cholangiocarcinoma following surgical resection: a meta-analysis for the 5-year survival.

Authors:  U F Wellner; YinFeng Shen; T Keck; WenYin Jin; Ze Xu
Journal:  Surg Today       Date:  2016-05-28       Impact factor: 2.549

6.  Hepatic resection for liver metastases from carcinomas of the distal bile duct and of the papilla of Vater.

Authors:  Isao Kurosaki; Masahiro Minagawa; Chie Kitami; Kabuto Takano; Katsuyoshi Hatakeyama
Journal:  Langenbecks Arch Surg       Date:  2011-02-24       Impact factor: 3.445

7.  Evaluation of UICC-TNM and JSBS staging systems for surgical patients with extrahepatic cholangiocarcinoma.

Authors:  Ryoko Sasaki; Soichiro Murata; Tatsuya Oda; Nobuhiro Ohkohchi; Yuichiro Takeda; Go Wakabayashi
Journal:  Langenbecks Arch Surg       Date:  2010-04-01       Impact factor: 3.445

8.  Over 700 Whipples for Pancreaticobiliary Malignancies: Postoperative Morbidity Is an Additional Negative Prognostic Factor for Distal Bile Duct Cancer.

Authors:  Stefano Andrianello; Giovanni Marchegiani; Giuseppe Malleo; Borislav Chavdarov Rusev; Aldo Scarpa; Deborah Bonamini; Laura Maggino; Claudio Bassi; Roberto Salvia
Journal:  J Gastrointest Surg       Date:  2016-11-23       Impact factor: 3.452

9.  Pancreaticoduodenectomy for secondary periampullary cancer following extrahepatic bile duct cancer resection.

Authors:  Dong Hun Kim; Dong Wook Choi; Seong Ho Choi; Jin Seok Heo
Journal:  Ann Surg Treat Res       Date:  2014-07-29       Impact factor: 1.859

10.  Proposal for a new T-stage classification system for distal cholangiocarcinoma: a 10-institution study from the U.S. Extrahepatic Biliary Malignancy Consortium.

Authors:  Lauren M Postlewait; Cecilia G Ethun; Nina Le; Timothy M Pawlik; Stefan Buettner; George Poultsides; Thuy Tran; Kamran Idrees; Chelsea A Isom; Ryan C Fields; Bradley Krasnick; Sharon M Weber; Ahmed Salem; Robert C G Martin; Charles Scoggins; Perry Shen; Harveshp D Mogal; Carl Schmidt; Eliza Beal; Ioannis Hatzaras; Gerardo Vitiello; Kenneth Cardona; Shishir K Maithel
Journal:  HPB (Oxford)       Date:  2016-08-09       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.